Bronchogen
AEDL Tetrapeptide · Bronchial Bioregulator
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.
Overview
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Supports bronchial tissue through gene expression regulation.
Helps maintain respiratory epithelium health.
Regulates protein synthesis in lung tissue.
Addresses age-related changes in bronchial tissue.
Modulates gene expression in respiratory cells.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tetrapeptide bioregulator
- Chain length
- 4 residues
- Molecular weight
- 432 Da
- Typical dose
- 10-20 mg oral or 10 mg injectable
- Frequency
- Daily for 10-20 days per cycle
- Cycle length
- 10-20 days
- Storage
- Oral capsules: room temperature. Injectable: 2-8°C refrigerated
Molecular data
- Type
- Tetrapeptide bioregulator
- Molecular weight
- 432 Da
- Chain length
- 4 residues
AEDLDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Research protocol | IM or SubQ | 10 mg | Daily for 10 days |
Interactions
Related respiratory bioregulators; complementary mechanisms.
Often combined in comprehensive anti-aging Khavinson protocols.
Both have immune-modulating properties; different tissue targets.
Part of Khavinson bioregulator family; targets different tissue.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual respiratory symptoms
- Active respiratory emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
FAQ
How do Khavinson bioregulator peptides work if their half-life is just minutes?
Bronchogen's tetrapeptide structure allows it to penetrate cell nuclei directly and modulate gene expression epigenetically. Despite its short circulating half-life, it triggers lasting changes in DNA regulation and protein synthesis in bronchial tissue. These epigenetic changes persist long after the peptide itself clears circulation.
What respiratory benefits have been proven in human trials for Bronchogen?
Clinical evidence on Bronchogen specifically is limited. Most research comes from Russian sources showing improvements in respiratory function when combined with other Khavinson peptides. Clear human efficacy data from double-blind trials doesn't exist in English-language literature.
Can I combine Bronchogen with other respiratory support supplements?
Yes. Bronchogen's epigenetic mechanism complements other approaches. It pairs well with standard respiratory support compounds, though no specific clinical data on combinations exists. Other Khavinson peptides like Chonluten target related respiratory systems synergistically.
How long before I notice respiratory improvements on Bronchogen?
Bronchogen works through gene expression changes that occur during the 10-20 day cycle. Noticeable respiratory improvements typically emerge weeks to months after cycles complete as the epigenetic changes take effect. Results improve with repeated 2-3 cycles yearly for cumulative benefits.